BCRX
Price
$7.78
Change
+$0.03 (+0.39%)
Updated
Oct 22 closing price
Capitalization
1.99B
11 days until earnings call
Intraday BUY SELL Signals
BEAM
Price
$24.56
Change
-$0.28 (-1.13%)
Updated
Oct 22 closing price
Capitalization
2.54B
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCRX vs BEAM

BCRX vs BEAM Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BCRX vs. BEAM commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and BEAM is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BCRX with price predictions
Oct 22, 2026

BCRX's Indicator enters downward trend

The Aroon Indicator for BCRX entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 201 similar instances where the Aroon Indicator formed such a pattern. In 161 of the 201 cases the stock moved lower. This puts the odds of a downward move at 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCRX as a result. In 76 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for BCRX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 40 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BCRX's RSI Oscillator exited the oversold zone, 31 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.376) is normal, around the industry mean (10.407). P/E Ratio (-5.763) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (2.097) is also within normal values, averaging (178.797).

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. BCRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
a Summary for BEAM with price predictions
Oct 22, 2026

Momentum Indicator for BEAM turns negative, indicating new downward trend

BEAM saw its Momentum Indicator move below the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 78 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for BEAM entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BEAM's RSI Oscillator exited the oversold zone, 20 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 59 cases where BEAM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Moving Average Convergence Divergence (MACD) for BEAM just turned positive on September 29, 2026. Looking at past instances where BEAM's MACD turned positive, the stock continued to rise in 42 of 52 cases over the following month. The odds of a continued upward trend are 81%.

Following a +6.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in 196 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.376) is normal, around the industry mean (2.973). P/E Ratio (-35.594) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (15.314) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. BEAM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
BCRX vs BEAM: Fundamental Ratings
BCRX
BEAM
OUTLOOK RATING
1..100
6672
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
5
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10092
PRICE GROWTH RATING
1..100
6269
P/E GROWTH RATING
1..100
9832
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (5) in the null industry is in the same range as BCRX (14) in the Biotechnology industry. This means that BEAM’s stock grew similarly to BCRX’s over the last 12 months.

BEAM's Profit vs Risk Rating (100) in the null industry is in the same range as BCRX (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to BCRX’s over the last 12 months.

BEAM's SMR Rating (92) in the null industry is in the same range as BCRX (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's Price Growth Rating (62) in the Biotechnology industry is in the same range as BEAM (69) in the null industry. This means that BCRX’s stock grew similarly to BEAM’s over the last 12 months.

BEAM's P/E Growth Rating (32) in the null industry is significantly better than the same rating for BCRX (98) in the Biotechnology industry. This means that BEAM’s stock grew significantly faster than BCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXBEAM
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 4 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
73%
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 1 day ago
84%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
85%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (BCRX: $7.78 vs. BEAM: $24.56)
Brand notoriety: BCRX: Notable vs. BEAM: Not notable
BCRX represents the Pharmaceuticals: Generic, while BEAM is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 87% vs. BEAM: 71%
Market capitalization -- BCRX: $1.99B vs. BEAM: $2.54B
BCRX [@Pharmaceuticals: Generic] is valued at $1.99B. BEAM’s [@Biotechnology] market capitalization is $2.54B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.32B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green while BEAM’s FA Score has 2 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • BEAM’s FA Score: 2 green, 3 red.
According to our system of comparison, BEAM is a better buy in the long-term than BCRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 2 TA indicator(s) are bullish while BEAM’s TA Score has 4 bullish TA indicator(s).

  • BCRX’s TA Score: 2 bullish, 4 bearish.
  • BEAM’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than BCRX.

Price Growth

BCRX (@Pharmaceuticals: Generic) experienced а -2.99% price change this week, while BEAM (@Biotechnology) price change was -0.69% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.00%. For the same industry, the average monthly price growth was -9.86%, and the average quarterly price growth was +9.31%.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

BCRX is expected to report earnings on Nov 02, 2026.

BEAM is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.00% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BCRX
Daily Signal:
Gain/Loss:
BEAM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-1.13%
CRSP - BEAM
77%
Closely correlated
-1.01%
EDIT - BEAM
66%
Closely correlated
-0.80%
PRME - BEAM
64%
Loosely correlated
-2.10%
NTLA - BEAM
59%
Loosely correlated
-4.21%
RXRX - BEAM
59%
Loosely correlated
-1.65%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PSFM35.76N/A
N/A
Pacer Swan SOS Flex (April) ETF (PSFM)
YBTY9.23-0.12
-1.34%
GraniteShares YieldBoost TopYielders ETF (YBTY)
DALI27.09-0.51
-1.85%
First Trust Dorsey Wright DALI Equity ETF (DALI)
FPX170.03-5.51
-3.14%
First Trust US Equity Opportunities ETF (FPX)
SGDJ76.73-5.77
-6.99%
Sprott Junior Gold Miners ETF (SGDJ)